Ernexa Therapeutics Inc. (ERNA) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Ernexa Therapeutics Inc. (ERNA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Ernexa Therapeutics Inc., analysts forecast revenue falling from $32.81M in 2025 to $0 in 2030; the average estimate for 2030 earnings per share is −$1.65; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Ernexa Therapeutics Inc. (ERNA) forecast — frequently asked questions
What are analysts forecasting for Ernexa Therapeutics Inc.'s earnings?
The average analyst estimate for Ernexa Therapeutics Inc. (ERNA) earnings per share in 2030 is -1.65, with individual estimates between -1.65 and -1.65.
How much revenue is Ernexa Therapeutics Inc. expected to make?
Analysts forecast Ernexa Therapeutics Inc. (ERNA) revenue of $0 in 2030, based on 1 published estimates.
How many analysts cover ERNA?
1 analyst contribute estimates for Ernexa Therapeutics Inc. (ERNA). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.